ContraFect Corp (CFRX)

NASDAQ
3.95
-0.16(-3.89%)
After Hours
4.07
+0.12(+3.038%)
- Real-time Data
  • Volume:
    766,290
  • Bid/Ask:
    3.97/4.07
  • Day's Range:
    3.93 - 4.12

CFRX Overview

Prev. Close
4.11
Day's Range
3.93-4.12
Revenue
-
Open
4.02
52 wk Range
3.44-8
EPS
-1.17
Volume
766,290
Market Cap
155.36M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
651,034
P/E Ratio
-
Beta
0.93
1-Year Change
-38.95%
Shares Outstanding
39,332,721
Next Earnings Date
Aug 12, 2021
What is your sentiment on ContraFect Corp?
or
Market is currently closed. Voting is open during market hours.

ContraFect Corp News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellSellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

ContraFect Corp Company Profile

ContraFect Corp Company Profile

Employees
33

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.

Read More
  • what a come back.
    0
    • this Is manipulated
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.